Synthorx Revenue and Competitors
Estimated Revenue & Valuation
- Synthorx's estimated annual revenue is currently $3.3M per year.
- Synthorx received $63.0M in venture funding in May 2018.
- Synthorx's estimated revenue per employee is $162,750
- Synthorx's total funding is $76.1M.
Employee Data
- Synthorx has 20 Employees.
- Synthorx grew their employee count by -29% last year.
Synthorx Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Synthorx?
Synthorx Inc. is a biotechnology company using synthetic biology to discover and develop novel protein therapeutics. Synthorx's expanded genetic alphabet platform has the unique ability to drive the site-specific incorporation of multiple synthetic amino acids into proteins thereby tuning receptor specificity important for improving efficacy and safety. In addition, their engineered organisms provide the ability to manufacture these improved proteins, called Synthorins, with the required fidelity and yield. The unique Synthorx platform expands the chemical and structural repertoire of protein therapeutics and uncovers new ways to modulate pharmacological properties of biologics, not possible with other technologies. The company was founded based on important discoveries in Dr. Floyd Romesberg's lab at The Scripps Research Institute in conjunction with Avalon Ventures, which housed Synthorx in its incubator, COI Pharmaceuticals, Inc. The company is headquartered in La Jolla, Calif.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$76.1M
Total Funding
20
Number of Employees
$3.3M
Revenue (est)
-29%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Synthorx's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Scientist I | Reveal Email/Phone |
2 | Senior Research Associate | Reveal Email/Phone |
3 | Director Laboratory Operations | Reveal Email/Phone |
4 | President | Reveal Email/Phone |
5 | Laboratory Manager | Reveal Email/Phone |
Synthorx News
Jan-2020: Sanofi completed the acquisition of Synthorx, a clinical-stage biotechnology company. Through this collaboration, Sanofi aimed to...
SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (THOR), a clinical-stage biotechnology company developing optimized ...
ValuEngine upgraded shares of Synthorx (NASDAQ:THOR) from a hold rating to a buy rating in a research report sent to investors on Thursday, ...
Floyd Romesberg, Ph.D., the renowned Scripps Research scientist and scientific founder of synthetic cytokine biotech Synthorx, has bid the ...
Other Companies in La Jolla
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.3M | 20 | -17% | N/A |
#2 | $3.1M | 20 | 33% | N/A |
#3 | $4.6M | 20 | -20% | N/A |
#4 | $2M | 20 | 11% | N/A |
#5 | $2M | 20 | -9% | N/A |
Synthorx Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-05-09 | $Undisclosed | Undisclosed | Avalon Ventures | Article |
| 2014-06-10 | $3.1M | Undisclosed | Article | |
| 2016-07-20 | $10.0M | B | RA Capital Management | Article |
| 2018-05-01 | $63.0M | C | OrbiMed | Article |